April 19, 2011
« Back to news listQMCF Technology has been licensed to GSK Biologicals for evaluation
Icosagen Cell Factory announced today it has signed an agreement for GlaxoSmithKline Biologicals (GSK Biologicals) to evaluate the QMCF Technology with an option, if successful, to proceed with a license to use the Technology for research activities.
QMCF Technology is a simple and efficient method for production of any kind of proteins for research use or for development of biological therapeutics. The uniqueness of the technology bases on the use of a proprietary combination of regulatory elements in mammalian QMCF cells that ensure stable replication and maintenance of the QMCF plasmids. The extended episomal maintenance (up to 2 months) allows high productivities and fast cell bank generation of the transfected cells. In addition, the technology is applicable to development cell-based assays for drug target screening. The Technology has been granted by European and US Patent.
About Icosagen Cell Factory
Icosagen Cell Factory OÜ was established in 2005. The company is dedicated to the development of the portfolio of QMCF Technology-based applications. The R&D work during 2005-2008 was performed in collaboration with Tartu University and financed by Enterprise Estonia.
Contact Information:
Icosagen Cell Factory OÜ
Marit Jaaska, Business Development Manager
E-mail: marit.jaaska@quattromed.com
Phone: +372 737 7070
